Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics.
Porous hydroxyapatite (HA) ceramics were combined with either allogeneic (ACI) or isogeneic (Fischer 344) rat marrow cells and implanted in subcutaneous sites of Fischer rats. FK506 as an immunosuppressant or saline was administered to the recipient rats. The implanted marrow/HA composites were harvested on day 28 and analyzed for bone-forming capability by determining osteoblastic phenotype expression levels of protein synthesis and gene expression. The alkaline phosphatase (ALP) activity and osteocalcin (OC) contents were very low and mRNAs (Northern blot analysis) were not detected in the allografts without FK506. However, high activity of ALP and high content of OC were found and mRNAs were detected in the allografts with FK506 and in the isografts (with and without FK506). This analysis indicates the osteogenic potential of allogeneic marrow cells in the presence of FK506. The histologic sections revealed that allografts without FK506 did not show bone formation but did show the infiltration of many small cells in the ceramics indicating an immunologic reaction, however, the allografts with FK506 and the isografts (with and without FK506) showed consistent de novo bone formation on the HA pore surface. These results indicate that FK506 can suppress the immunologic reaction in the allografts and induce a favorable conditions to support osteoblastic differentiation of allogeneic rat marrow stromal stem cells on the surface of HA ceramics. Therefore, our study suggests the feasibility of clinical transplantation of allogeneic bone marrow for a selected bone graft in applications using adjuvant systemic immunosuppression.
Akahane
M
M
Department of Orthopedic Surgery, Nara Medical University, Japan.
Ohgushi
H
H
Yoshikawa
T
T
Sempuku
T
T
Tamai
S
S
Tabata
S
S
Dohi
Y
Y
D000469:Alkaline Phosphatase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000473:pathology* / Q000502:physiology; D002516:Ceramics; D015870:Gene Expression; D006882:Hydroxyapatites; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010012:Osteogenesis; D010641:Phenotype; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011912:Rats, Inbred ACI; D011916:Rats, Inbred F344; D016559:Tacrolimus / Q000008:administration & dosage; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D006882:Hydroxyapatites; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D016559:Tacrolimus